國家衛生研究院 NHRI:Item 3990099045/7472
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 860472      線上人數 : 650
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7472


    題名: Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    作者: Finn, RS;Poon, RTP;Yau, T;Klümpen, HJ;Chen, LT;Kang, YK;Kim, TY;Gomez-Martin, C;Rodriguez-Lope, C;Kunz, T;Paquet, T;Brandt, U;Sellami, D;Bruix, J
    貢獻者: National Institute of Cancer Research
    摘要: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). Combination therapy targeting multiple signaling pathways may improve outcomes. This phase I study was designed to determine the maximum tolerated dose (MTD) of everolimus given with sorafenib 400 mg twice daily in patients with advanced HCC of Child-Pugh class A liver function who were naive to systemic therapy. Methods Everolimus was initiated at 2.5 mg once daily and increased per a Bayesian sequential dose-escalation scheme based on the dose-limiting toxicities experienced within the first 28 days of treatment. Adverse events were assessed continuously. Efficacy was evaluated using the best overall response rate per RECIST. Results Thirty patients were enrolled; 25 were evaluable for MTD determination. One of 12 patients treated with everolimus 2.5 mg once daily and 6 of 13 patients treated with everolimus 5.0 mg once daily experienced a dose-limiting toxicity, most commonly thrombocytopenia (n=5). All patients experienced ⩾1 adverse event, most commonly diarrhea (66.7%), hand-foot skin reaction (66.7%), and thrombocytopenia (50.0%). Best overall response was stable disease (62.5% and 42.9% in the 2.5-mg and 5.0-mg cohorts, respectively). Median time to progression and overall survival in the 2.5-mg cohort were 4.5 months and 7.4 months, respectively, and 1.8 months and 11.7 months, respectively, in the 5.0-mg cohort. Conclusions In patients with advanced HCC, the everolimus MTD in combination with standard-dose sorafenib was 2.5 mg once daily. The inability to achieve a biologically effective everolimus concentration at the MTD precluded phase II study of this combination.
    日期: 2013-12
    關聯: Journal of Hepatology. 2013 Dec;59(6):1271-1277.
    Link to: http://dx.doi.org/10.1016/j.jhep.2013.07.029
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8278&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000327141800018
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84887993101
    顯示於類別:[陳立宗] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SDO0168827813005448.pdf594KbAdobe PDF495檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋